← All trials
NCT07300059
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2026
- Primary completion
- Aug 15, 2026
- Completion date
- Aug 28, 2026
- First posted
- Dec 23, 2025
- Last posted
- Dec 23, 2025
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aspargo Labs, IncLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.